IRX THERAPEUTICS

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.